MX2010003762A - Vacuna preventiva contra vih a base de anticuerpos especificos contra vih. - Google Patents

Vacuna preventiva contra vih a base de anticuerpos especificos contra vih.

Info

Publication number
MX2010003762A
MX2010003762A MX2010003762A MX2010003762A MX2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A
Authority
MX
Mexico
Prior art keywords
hiv
present
specific antibodies
peptides
polypeptides
Prior art date
Application number
MX2010003762A
Other languages
English (en)
Spanish (es)
Inventor
Elena Yu Filinova
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Publication of MX2010003762A publication Critical patent/MX2010003762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010003762A 2007-10-09 2008-10-09 Vacuna preventiva contra vih a base de anticuerpos especificos contra vih. MX2010003762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (1)

Publication Number Publication Date
MX2010003762A true MX2010003762A (es) 2010-09-10

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003762A MX2010003762A (es) 2007-10-09 2008-10-09 Vacuna preventiva contra vih a base de anticuerpos especificos contra vih.

Country Status (12)

Country Link
US (1) US20100215695A1 (enExample)
EP (1) EP2205736B1 (enExample)
JP (1) JP2010540674A (enExample)
KR (1) KR20100098597A (enExample)
CN (1) CN101970659A (enExample)
AU (1) AU2008309940B2 (enExample)
BR (1) BRPI0818354A2 (enExample)
CA (1) CA2701948A1 (enExample)
MX (1) MX2010003762A (enExample)
RU (1) RU2505604C2 (enExample)
WO (1) WO2009046984A1 (enExample)
ZA (1) ZA201002445B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
WO2013040564A2 (en) * 2011-09-17 2013-03-21 Nanjing University Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
RU2600031C2 (ru) * 2014-11-11 2016-10-20 Публичное акционерное общество "Фармсинтез" Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения
EP4276106A3 (en) * 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
US11067583B2 (en) 2016-05-25 2021-07-20 University Of Maryland, Baltimore Methods of making active antibodies from biological fluids
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
EP3641806A4 (en) 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Also Published As

Publication number Publication date
RU2505604C2 (ru) 2014-01-27
AU2008309940B2 (en) 2013-11-14
CN101970659A (zh) 2011-02-09
WO2009046984A1 (en) 2009-04-16
ZA201002445B (en) 2011-03-30
AU2008309940A1 (en) 2009-04-16
JP2010540674A (ja) 2010-12-24
CA2701948A1 (en) 2009-04-16
EP2205736B1 (en) 2014-04-02
US20100215695A1 (en) 2010-08-26
BRPI0818354A2 (pt) 2017-05-16
EP2205736A1 (en) 2010-07-14
RU2010116849A (ru) 2011-11-20
KR20100098597A (ko) 2010-09-08

Similar Documents

Publication Publication Date Title
WO2010009346A3 (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2008063331A3 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
MY145614A (en) Vaccine
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2012046061A3 (en) Clostridium difficile antigens
WO2004065417A3 (en) Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
EA201100668A1 (ru) Способы продуцирования антител из плазматических клеток
WO2017079479A8 (en) Neutralizing antibodies to hiv-1 gp41 and their use
IN2009CN03372A (enExample)
CY1115927T1 (el) Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2
WO2011153400A3 (en) Nasal immunization
WO2009099777A3 (en) Chimeric hiv fusion proteins as vaccines
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
EP2293079A3 (en) Use of precursors of enkephalins and/or their fragments in medical diagnostics
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
WO2021252406A3 (en) Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof
Wang et al. Comprehensive characterization of reference standard lots of HIV-1 subtype C Gp120 proteins for clinical trials in Southern African regions
WO2004041852A3 (en) Hiv vaccine
WO2009129521A3 (en) Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
WO2020047263A3 (en) Sequential immunization strategies to guide the maturation of antibodies against human immmunodeficiency virus
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.

Legal Events

Date Code Title Description
FG Grant or registration